OECHSLER presents own market appearance for its business unit OECHSLERhealth
- New brand is the next logical step in implementing the growth strategy of the polymer technology specialist in the global market for medical technology
- OECHSLERhealth is successfully expanding its customer portfolio and is fully on track to exceed the revenue threshold of 100 million euros by 2028
- Strengthening of the strategic growth area health with investment in the single-digit millions and expansion of the international cleanroom network
Learn more about OECHSLERhealth
Ansbach, 12. September 2023 --- OECHSLER AG (“OECHSLER”), a leading polymer technology group with a global presence and headquarters in Ansbach/Middle Franconia, today presented a new and dedicated brand for its health business unit: Under OECHSLERhealth, with its own website (www.oechsler-health.com), logo and social media presence, the company's global business with medical products will be marketed with immediate effect. The new brand is a further step of the implementation of the growth offensive of the health business unit launched by OECHSLER 2022. The growth strategy is based on investments in the key areas of human resources and process development as well as infrastructure, and is geared to the worldwide increase in demand in the field of medical technology, with the aim of successively expanding the global customer and product portfolio.
The Franconian technology company is working on exceeding the revenue threshold of 100 million euros in its strategic growth business with medical products by 2028. In fiscal year 2022, OECHSLERhealth has already recorded a significant jump in sales of 28 percent to EUR 19 (2021: 15) million and is successfully continuing its growth course in the current fiscal year. Within a year, OECHSLERhealth has already acquired two globally active pharmaceutical companies as new customers. OECHSLERhealth supports these customers throughout the entire process, from concept development to successful market launch and series production, thus positioning itself specifically as a ”Contract Manufacturing Organization” (CMO) for MedTech OEMs and the pharmaceutical industry. The company sees significant future growth potential particularly in the product categories of drug delivery systems, diagnostics and minimally invasive surgical technologies.
1,300 sqm new cleanroom capacity, at least another 500 sqm planned
As part of its growth offensive, OECHSLERhealth is significantly expanding its global production capacities for medical devices: By 2024, the company will invest a higher single-digit million euro amount in the global expansion of new cleanroom areas in accordance with DIN ISO 7 and 8 or GMP Class C & D. At the headquarters in Ansbach, the expansion of cleanroom capacity by 50 percent to 2,000 square meters has already been completed, with a further 500 square meters planned. At the Mexico site, completion of a new cleanroom with 650 square meters is imminent. The first expansion stage is already laying the groundwork for the next expansion step of an additional 500 square meters. Further measures are planned for the sites in Romania and China over the next few years.
Significant increase in global demand for medical products
The global healthcare market is considered highly dynamic with long-lasting product cycles that require rapid innovations with the greatest possible flexibility for customer requirements. In Germany alone, there are around 500,000 different medical products on the market. Here, OECHSLERhealth benefits from its extensive experience in manufacturing these products. For example, the company has been producing inhalers, blood glucose meters and pipettes for numerous well-known customers in the industry worldwide for over 30 years. Decisive factors in this long-standing success are, in particular, the high standards of quality and precision, a broadly diversified technology portfolio and the company's international presence. The global healthcare market, which is worth over one trillion euros, will grow significantly in the coming years. The trend is towards home treatment; people want to be able to carry out medically necessary treatments as individually and independently as possible. In the inhaler category, for example, market research institutes forecast average annual growth of 7 percent up to 2030. For blood glucose meters, the expected annual growth is as high as 11 percent. Around 500 million people worldwide already suffer from diabetes, and the trend is rising.
Raik Lüder, Chief Products & Markets Officer von OECHSLER, said: “The market for medical technology is a dynamic, future oriented market that offers us great opportunities. Life expectancy and people's standard of living are increasing continuously, which results into more people require medical devices such as inhalers, blood glucose meters or pipettes and catheters in their everyday lives. At OECHSLER, we not only have the right technological solutions for the production of medical devices, but also the corresponding experience and an international production network. It is therefore only logical that we give our growth offensive in the health sector a greater presence and a special boost with our own business unit OECHSLERhealth.”
Felix Hess, Vice President Sales OECHSLERhealth, added: “We are pursuing an ambitious growth plan with OECHSLERhealth that we are implementing step by step. The new market presence of the Health business unit and the significantly expanded cleanroom areas for the production of medical products are two important milestones on the way to increasing our sales in this area to 100 million euros by 2028. Furthermore, we are continuously optimizing our processes in order to be a reliable development and industrialization partner for our global customers at all times and at every stage for precisely tailored manufacturing solutions for high-quality medical devices. In this way, we are preparing our organization for the dynamic growth in demand in the coming years.”
Note to editors:
About OECHSLER
Founded in 1864 by Matthias Oechsler and headquartered in Germany, OECHSLER AG is a leading polymer technology group supplying customers worldwide in the automotive, healthcare, industrial technology and sporting goods sectors. In addition to the production of precision polymer parts and components, OECHSLER AG also offers services in product development, prototyping, product management and highly specialized toolmaking. The company's customers include international industrial and healthcare groups as well as leading automotive suppliers and leading companies in the sporting goods industry.
The corporate group achieved a turnover of 380 million euros in 2022. The OECHSLER Group employed at of the annual average 2022 around 2,950 people (Germany 1,324, abroad 1,626) at the production sites in Ansbach, Ansbach-Brodswinden and Weißenburg as well as at the Chinese subsidiary OECHSLER Plastic Products (Taicang) Co. Ltd. in Taicang, OECHSLER Romania s.r.l. in Lipova, OECHSLER Mexico S.A. de C.V. in Querétaro and OECHSLER Motion LLC in Long An (Vietnam). The descendants of the company's founder still hold 79 percent of the share capital of OECHSLER AG. In addition to the management, the financial investor Deutsche Beteiligungs AG (DBAG) holds 20 percent of the company. Further information at: www.oechsler.com/en
On behalf of OECHSLER AG:
Charles Barker Corporate Communications GmbH
Contact: Hans Bielefeld and Tobias Anslinger
Tel. +49 69/79 40 90 -44 / -41, oechsler@charlesbarker.de
